Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

45.94 -0.28 (-0.61%)
Delayed Quote Updated: 3:12 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
From Veracyte, Inc.
Via Business Wire
Expert Ratings For Veracyte ↗
Within the last quarter, Veracyte (NASDAQ:VCYT) has observ... 
Via Benzinga
News headline image
Expert Ratings for Veracyte ↗
Analysts have provided the following ratings for Veracyte (NASDAQ:VCYT) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 0... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
From Veracyte, Inc.
Via Business Wire
News headline image
Mid-Cap Biotech Picks: Seasonal Rally Underway ↗
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
News headline image
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
From Veracyte, Inc.
Via Business Wire
News headline image
Looking Into Veracyte's Return On Capital Employed ↗
During Q1, Veracyte's (NASDAQ:VCYT) reported sales totaled $36.70 million. Despite a 462.62% in earnings, the company posted a loss of $45.41 million. Veracyte collected $34.54... 
Via Benzinga
News headline image
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 ↗
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
News headline image
Veracyte: Return On Capital Employed Insights ↗
In Q1, Veracyte (NASDAQ:VCYT) posted sales of $36.70 million. Earnings were up 462.62%, but Veracyte still reported an overall loss of $45.41 million. Veracyte collected $34.54... 
Via Benzinga
News headline image
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
From Veracyte, Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Strengthens Cancer Diagnostics Portfolio with HalioDx Acquisition ↗
Veracyte Inc (NASDAQ: VCYT) has agreed to acquire HalioDx in a €260 million transaction to accelerate growth and strengthen its position in cancer diagnostics... 
Via Benzinga
News headline image
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Present at Upcoming Investor Conferences
From Veracyte
Via Business Wire
News headline image
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Present at Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
From Veracyte
Via Business Wire
News headline image
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
From Veracyte, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Celyad Oncology (NASDAQ:CYAD) sto... 
Via Benzinga
News headline image
Cathie Wood Loads Up $57M In Palantir As Stock Stages Reversal On Q1 Earnings Beat ↗
Cathie Wood-led Ark Investment Management on Tuesday snapped up 2.8 million shares, worth about $56.7 million, in Palantir Technologies Inc (NYSE: PLTR) after the data analytics... 
Via Benzinga
News headline image
Veracyte, Inc. Announces CEO Succession Plan
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings ↗
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
News headline image
Veracyte Announces First Quarter 2021 Financial Results
From Veracyte, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.